Enlivex Therapeutics Ltd.
ENLV
Price:
$1.3
Market Cap:
$27.83M
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.[Read more]
Industry
Biotechnology
IPO Date
2014-07-31
Stock Exchange
NASDAQ
Ticker
ENLV
PE Ratio
[-1.10]
ROE
[-71.76%]
Current Ratio
[10.06]
Dividend Yield
[0%]
Enterprise Value
[24.80M]
Dividend History
The ROE as of November 2024 (TTM) for Enlivex Therapeutics Ltd. (ENLV) is -71.76%
According to Enlivex Therapeutics Ltd.’s latest financial reports and current stock price. The company's current ROE is -71.76%. This represents a change of 299.39% compared to the average of -17.97% of the last 4 quarters.
Enlivex Therapeutics Ltd. (ENLV) Historical ROE (quarterly & annually)
How has ENLV ROE performed in the past?
The mean historical ROE of Enlivex Therapeutics Ltd. over the last ten years is -83.61%. The current -71.76% ROE has changed -14.17% with respect to the historical average. Over the past ten years (40 quarters), ENLV's ROE was at its highest in in the March 2020 quarter at -2.48%. The ROE was at its lowest in in the March 2017 quarter at -42.63%.
Average
-83.61%
Median
-80.15%
Minimum
-188.01%
Maximum
-11.35%
Enlivex Therapeutics Ltd. (ENLV) ROE by Quarter and Year
Discovering the peaks and valleys of Enlivex Therapeutics Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 557.59%
Maximum Annual ROE = -11.35%
Minimum Annual Increase = -76.75%
Minimum Annual ROE = -188.01%
| Year | ROE | Change |
|---|---|---|
| 2023 | -96.62% | 29.51% |
| 2022 | -74.61% | 557.59% |
| 2021 | -11.35% | -70.96% |
| 2020 | -39.07% | -56.57% |
| 2019 | -89.96% | 105.83% |
| 2018 | -43.70% | -76.75% |
| 2017 | -188.01% | 2.08% |
| 2016 | -184.18% | 114.95% |
| 2015 | -85.68% | 274.29% |
| 2014 | -22.89% | 11.06% |
Enlivex Therapeutics Ltd. (ENLV) Average ROE
How has ENLV ROE performed in the past?
The current ROE of Enlivex Therapeutics Ltd. (ENLV) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-60.86%
5-year avg
-62.32%
10-year avg
-83.61%
Enlivex Therapeutics Ltd. (ENLV) ROE vs. Peers
How is ENLV’s ROE compared to its peers?
Enlivex Therapeutics Ltd.’s ROE is greater than Pluri Inc. (-482.73%), greater than BioLineRx Ltd. (-225.62%), greater than Purple Biotech Ltd. (-48.16%), greater than Aridis Pharmaceuticals, Inc. (-62.63%), greater than Histogen Inc. (-80.73%), greater than PMV Pharmaceuticals, Inc. (-21.96%), greater than Aptevo Therapeutics Inc. (-266.14%), greater than Protalix BioTherapeutics, Inc. (-45.15%), greater than Corvus Pharmaceuticals, Inc. (-53.99%), greater than Phio Pharmaceuticals Corp. (-142.68%), greater than Rain Therapeutics Inc. (-81.52%), greater than CollPlant Biotechnologies Ltd. (-65.98%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Merus N.V. (-45.38%), less than Vericel Corporation (0.35%), greater than Century Therapeutics, Inc. (-65.37%), greater than Aldeyra Therapeutics, Inc. (-33.33%), less than Gamida Cell Ltd. (187.96%), less than Checkpoint Therapeutics, Inc. (292.43%),
| Company | ROE | Market cap |
|---|---|---|
| -482.73% | $24.94M | |
| -225.62% | $37.41M | |
| -48.16% | $5.72M | |
| -62.63% | $8.91K | |
| -80.73% | $897.07K | |
| -21.96% | $84.49M | |
| -266.14% | $2.66M | |
| -45.15% | $94.13M | |
| -53.99% | $564.21M | |
| -142.68% | $2.76M | |
| -81.52% | $44.01M | |
| -65.98% | $42.50M | |
| -44.73% | $2.25B | |
| -45.38% | $3.51B | |
| 0.35% | $2.18B | |
| -65.37% | $106.74M | |
| -33.33% | $307.80M | |
| 187.96% | $4.34M | |
| 292.43% | $154.67M |
Build a custom stock screener for Enlivex Therapeutics Ltd. (ENLV) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Enlivex Therapeutics Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Enlivex Therapeutics Ltd. (ENLV) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Enlivex Therapeutics Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Enlivex Therapeutics Ltd.'s ROE?
How is the ROE calculated for Enlivex Therapeutics Ltd. (ENLV)?
What is the highest ROE for Enlivex Therapeutics Ltd. (ENLV)?
What is the 3-year average ROE for Enlivex Therapeutics Ltd. (ENLV)?
What is the 5-year average ROE for Enlivex Therapeutics Ltd. (ENLV)?
How does the current ROE for Enlivex Therapeutics Ltd. (ENLV) compare to its historical average?